ReviewExploration (Beijing, China)2025
Synthetic Biology-Based Engineering Cells for Drug Delivery.
Review in Exploration (Beijing, China), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Accelerating the clinical translation of bioengineered anticancer therapeutics.Journal of the National Cancer Center · 2026Article
- Liquid Metal Materials for Tumor Diagnosis and Treatment.Advanced healthcare materials · 2026Review
- Bioproduction of ∼10 knt single-stranded DNA for constructing large DNA origami structures.Materials today. Bio · 2026Article
- Advanced drug delivery platforms targeting cellular senescence: A promising strategy for cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- Review
- A 5-fluorouracil-loaded BSA-Pd nanozyme inducing ROS burst and mild photothermal therapy for potent eradication of colorectal cancer.Scientific reports · 2026Article
- T cell-inspired therapeutic delivery platforms: From nanomedicines to cell therapy.Materials today. Bio · 2026Review
- Engineered apoptotic vesicle mimetics with tunable "eat-me" signaling precisely regulate tumor-associated macrophages for potentiating cancer immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- Logic-Gated HSV-TK/GCV Suicide Gene Circuit for Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Biomarker-Guided Drug Delivery Systems and Oral Bioavailability Enhancement.Pharmaceuticals (Basel, Switzerland) · 2026Review
- TRIM13 in situ engineering boosts anti-inflammatory capacity of CAR-Ms for liver fibrosis therapy.Nature communications · 2026Article
- Synergistic mechanical and therapeutic modulation of engineered tumor cell-derived microparticles for enhanced cancer treatment.Cell reports. Medicine · 2026Article
- From Uptake to Therapeutic Function in Engineered Exosome Delivery Systems.Research (Washington, D.C.) · 2026Review
- Stimuli-Responsive Cell-Mimetic Vesicles for Advanced Pharmaceutical Systems.International journal of nanomedicine · 2026Review
- Legal, ethical and moral dilemma of human cloning: the conflict between technological progress and human dignity.Frontiers in medicine · 2026Review
- Demystifying anti-inflammatory therapeutic strategies against pancreatitis and concomitant diseases: a 2025 perspective.Theranostics · 2026Review
- The Cross-Species Implantable ATP Battery Inspired by Photosynthesis for Application in Diseases.International journal of nanomedicine · 2026Review
- Extracellular Vesicle-Mediated Delivery of Mitochondrial Circular RNA MTCO2 Protects against Cerebral Ischemia by Modulating mPTP-Dependent Ferroptosis.Research (Washington, D.C.) · 2026Article
- Cell-drug conjugates: a novel drug delivery system for cancer therapy.Theranostics · 2026Review
- Plant-derived extracellular vesicles as a natural drug delivery platform for glioblastoma therapy: A dual role in preserving endothelial integrity while modulating the tumor microenvironment.International journal of pharmaceutics: X · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although drug delivery technology has promoted the clinical translation of small molecule drugs, there is an urgent need for advanced delivery systems to overcome complex physiological barriers and the increasing development of biological drugs. This review overviews the emerging applications of synthetic biology-based engineered cells for drug delivery. We first introduce synthetic biology strategies to engineer cells for biological drug delivery and discuss the benefits in terms of specificity, intelligence, and controllability. Furthermore, we highlight the cutting-edge advancements at the convergence of synthetic biology and nanotechnology in drug delivery. Nanotechnology expands the engineering design and construction concepts of synthetic biology, and synthetic biology drives the development for biotechnology-driven nanomaterial synthesis. In the future, synthetic biology-based engineered cells may be developed to be more modular, standardized, and intelligent, leading to significant breakthroughs in the construction of advanced drug delivery systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.